We hypothesize that PLK1 inhibition may be effective in NSCLC with acquired EGFR-TKI resistance that had undergone EMT based on our own previous studies showed that mesenchymal NSCLC cell lines are more sensitive to PLK1 inhibition than epithelial cell lines are in vitro and in vivo [16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.